Q2 2026 13F · SEC CIK 1892770

Knott David M Jr

Investment managerFiled 2026-08-12 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $189.2M
Reported positions: 84
Top holdings a year, 3 yrs: +30.6%
Average holding period: 3.2 yrs

Knott David M Jr is an investment manager that reported 84 positions worth $189.2M in its Q2 2026 13F, filed 2026-08-12. Its largest holdings were Alphabet Inc (GOOG, 17.1%), Apollo Global Management Inc (APO, 14.1%), Syndax Pharmaceuticals Inc (SNDX, 5.1%). A portfolio copying its top holdings returned 30.6% a year over the last 3 years, against 22.3% for the S&P 500.

Knott David M Jr holdings largest 50 of 84 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Knott David M Jr 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
GOOGAlphabet Inc	17.1%	15.6%	91,420	+0.0%	$32.3M
APOApollo Global Management Inc	14.1%	14.9%	225,000	+0.0%	$26.6M
SNDXSyndax Pharmaceuticals Inc	5.1%	5.9%	437,245	+3.6%	$9.6M
XERSXeris Biopharma Holdings Inc	4.4%	3.7%	1,060,000	+0.0%	$8.4M
TVTXTravere Therapeutics Inc	4.4%	2.5%	147,282	+4.7%	$8.4M
PTGXProtagonist Therapeutics Inc	4.1%	4.0%	63,000	+0.0%	$7.7M
BBIOBridgebio Pharma Inc	3.7%	4.0%	92,850	+3.2%	$6.9M
IOVAIovance Biotherapeutics Inc	3.5%	3.3%	1,600,000	+0.0%	$6.7M
ALKSAlkermes PLC	3.4%	2.5%	121,759	+1.5%	$6.4M
JPMJpmorgan Chase & Co	3.1%	3.4%	18,098	-7.1%	$5.9M
JAAAJanus Detroit Str Tr	2.5%	2.8%	93,528	+0.0%	$4.7M
LPLALPL Financial Holdings Inc.	2.5%	3.0%	16,500	+0.0%	$4.6M
COGTCogent Biosciences Inc	2.3%	2.4%	111,081	+6.8%	$4.3M
TGTXTG Therapeutics Inc	1.9%	1.8%	66,839	-25.7%	$3.7M
CLSTCatalyst Bancorp Inc	1.9%	—	114,000	—	$3.6M
AGIOAgios Pharmaceuticals Inc	1.9%	1.9%	95,058	+2.1%	$3.5M
VRDNViridian Therapeutics Inc	1.8%	2.1%	181,000	+0.0%	$3.3M
RLMDRelmada Therapeutics Inc	1.6%	1.8%	451,000	+2.7%	$3.1M
RCUSArcus Biosciences Inc.	1.3%	1.0%	81,241	+0.0%	$2.5M
23256X407Cybin Inc	1.3%	1.0%	370,000	+5.7%	$2.4M
XBISpdr Series Trust	1.3%	1.1%	15,000	+0.0%	$2.4M
RZLTRezolute, Inc.	1.0%	0.7%	370,000	+0.0%	$1.9M
ABAlliancebernstein Hldg L P	0.9%	1.1%	48,000	+0.0%	$1.7M
MDGLMadrigal Pharmaceuticals Inc	0.9%	0.6%	3,000	+50.0%	$1.6M
ATRCAtriCure, Inc.	0.8%	0.9%	51,400	+0.0%	$1.4M
DCGODocGo, Inc.	0.7%	1.0%	2,670,850	+0.0%	$1.4M
ARDXArdelyx Inc	0.7%	0.7%	263,168	+27.1%	$1.3M
RAREUltragenyx Pharmaceutical in	0.7%	0.4%	38,069	+15.1%	$1.3M
CLOZSeries Portfolios Tr	0.7%	0.7%	47,807	+0.0%	$1.3M
CGEMCullinan Therapeutics Inc	0.7%	—	69,182	—	$1.3M
JNJJohnson & Johnson	0.7%	0.7%	4,922	+0.0%	$1.3M
VERAVera Therapeutics Inc Class A	0.6%	0.6%	26,000	+0.0%	$1.1M
OBIOOrchestra Biomed Hldgs Inc	0.6%	0.6%	253,651	+0.0%	$1.1M
85209E208Spruce Biosciences Inc	0.6%	—	20,000	—	$1.1M
CNTBConnect Biopharma Hldgs Ltd	0.6%	0.6%	444,862	+14.7%	$1.1M
IBBIshares Tr	0.6%	0.6%	5,500	+0.0%	$1.0M
BIIBBiogen Inc	0.5%	0.4%	4,000	+0.0%	$864K
PFEPfizer Inc	0.4%	0.5%	32,337	+0.0%	$779K
AAPLApple Inc	0.4%	0.4%	2,494	+0.0%	$722K
CNQCanadian Nat Res Ltd Med Ter	0.4%	0.5%	16,800	+0.0%	$664K
PTHSPelthos Therapeutics Inc	0.3%	0.3%	22,073	+4.7%	$624K
IBMInternational Business Machs	0.3%	0.3%	2,142	+0.0%	$602K
MSFTMicrosoft Corp	0.3%	0.4%	1,600	+0.0%	$597K
VSTMVerastem Inc	0.3%	0.3%	155,000	+49.0%	$592K
KURAKura Oncology Inc	0.3%	0.3%	52,767	+0.0%	$579K
SLDBSolid Bioscience Inc.	0.3%	—	56,208	—	$562K
36614N201DuPont de Nemours, Inc.	0.3%	—	3,767	—	$511K
INSMInsmed Inc	0.2%	—	4,253	—	$453K
LBRXLB Pharmaceuticals, Inc.	0.2%	—	12,965	—	$421K
CDNACareDx, Inc.	0.2%	—	13,630	—	$388K

What Knott David M Jr bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +30.0% /yr; S&P 500 +11.7%
3 years: +30.6% /yr; S&P 500 +22.3%
5 years: +18.2% /yr; S&P 500 +12.3%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$189.2M	84
Q1 2026	$168.0M	85
Q4 2025	$215.9M	87
Q3 2025	$238.7M	87
Q2 2025	$220.6M	85
Q1 2025	$212.0M	84
Q4 2024	$276.5M	89
Q3 2024	$284.6M	92
Q2 2024	$250.6M	99
Q1 2024	$282.8M	106
Q4 2023	$261.6M	113
Q3 2023	$261.9M	132

Questions about Knott David M Jr's portfolio

What stocks does Knott David M Jr own?

Knott David M Jr's latest 13F, for Q2 2026 and filed Aug 12, 2026, lists 84 positions worth $189.2M. The largest are Alphabet Inc (GOOG) at 17.1%, Apollo Global Management Inc (APO) at 14.1%, Syndax Pharmaceuticals Inc (SNDX) at 5.1%, Xeris Biopharma Holdings Inc (XERS) at 4.4% and Travere Therapeutics Inc (TVTX) at 4.4%.

What did Knott David M Jr buy last quarter?

In Q2 2026, Knott David M Jr added Madrigal Pharmaceuticals Inc (MDGL) (+50.0% shares), Verastem Inc (VSTM) (+49.0% shares) and Ardelyx Inc (ARDX) (+27.1% shares), compared with its Q1 2026 filing.

What did Knott David M Jr sell last quarter?

In Q2 2026, Knott David M Jr cut from its top 50 Catalyst Pharmaceuticals Inc (CPRX), cut from its top 50 Arcellx Inc (ACLX), cut from its top 50 Cytokinetics (CYTK), cut from its top 50 Centessa Pharmaceuticals PLC (CNTA), cut from its top 50 Bristol-Myers Squibb Co (BMY), TG Therapeutics Inc (TGTX) (-25.7% shares) and Jpmorgan Chase & Co (JPM) (-7.1% shares), compared with its Q1 2026 filing.

How has Knott David M Jr's portfolio performed?

A portfolio copying Knott David M Jr's 20 largest 13F holdings each quarter, from the day each filing was public, returned +30.6% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: +30.0% against +11.7%. Over 5 years: +18.2% a year against +12.3%.

When is Knott David M Jr's next 13F filing due?

13F filings are due 45 days after each quarter ends. Knott David M Jr's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.